Deals and Capital Markets

Mergers, acquisitions, licensing, partnerships, IPOs, and funding in biopharma. Covers who is paying for what, and why.

Page 1 of 1

Empty, set tables in a dimly lit restaurant, with black-and-white diner portraits on the wall above.

Milestone Monday: How Two Very Large Parties Helped Biotech’s IPO Year Reach $8.89bn

Nov 2, 2026 Capsul Desk 5 min read members

A pack of marathon runners seen from behind on a city street, some lit by low sun and others in shadow, with spectators and a brick apartment building in the background.

Milestone Monday: The Starting Gun Is Not The Finish Line

Oct 19, 2026 Aakash Babu 4 min read members

A reddish-brown retriever wearing black-framed glasses rests its chin on an open magazine, looking up at the camera.

Milestone Monday: Biopharma IPOs Are Playing To A Friendly House

Oct 5, 2026 Capsul Desk 6 min read members

The Long View: After 11 Years, 2 Months, 23 Days and One $62bn Deal, Weber Hands Takeda to Kim

Christophe Weber leaves a global top-ten drugmaker, and the debt it took to get there. The verdict now belongs to the executive who arrived in the very transaction that made it.

Jun 26, 2026 Capsul Desk 7 min read members